Get the Stockscreener App
10.15
4.00%
0.39
Wave Life Sciences Ltd stock is traded at $10.15, with a volume of 2.25M.
It is up +4.00% in the last 24 hours and up +27.99% over the past month.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
See More
Previous Close:
$9.76
Open:
$9.85
24h Volume:
2.25M
Relative Volume:
1.64
Market Cap:
$1.62B
Revenue:
$93.95M
Net Income/Loss:
$-129.87M
P/E Ratio:
-11.28
EPS:
-0.9
Net Cash Flow:
$-202.88M
1W Performance:
+4.00%
1M Performance:
+27.99%
6M Performance:
-8.81%
1Y Performance:
+83.88%
1-Day Range:
$9.72
$10.57
1-Week Range:
$9.26
$10.57
52-Week Range:
$5.04
$16.73
Wave Life Sciences Ltd Stock (WVE) Company Profile
Name
Wave Life Sciences Ltd
Sector
Industry
Phone
617-949-2900
Address
7 STRAITS VIEW, SINGAPORE
Compare WVE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
WVE
Wave Life Sciences Ltd
|
10.15 | 1.55B | 93.95M | -129.87M | -202.88M | -0.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-04-25 | Initiated | Canaccord Genuity | Buy |
| Jul-28-25 | Initiated | Oppenheimer | Outperform |
| Jul-16-25 | Initiated | Citigroup | Buy |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-25 | Initiated | Wedbush | Outperform |
| Feb-25-25 | Initiated | Jefferies | Buy |
| Oct-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-27-24 | Resumed | JP Morgan | Overweight |
| Sep-19-24 | Initiated | B. Riley Securities | Buy |
| Sep-09-24 | Initiated | JP Morgan | Overweight |
| May-15-24 | Initiated | Wells Fargo | Overweight |
| Dec-19-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-05-23 | Initiated | Raymond James | Outperform |
| May-24-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-31-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Jul-15-19 | Initiated | Cowen | Market Perform |
| Apr-17-19 | Reiterated | H.C. Wainwright | Buy |
| Aug-07-18 | Initiated | Stifel | Buy |
| Jul-23-18 | Initiated | H.C. Wainwright | Buy |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Feb-15-17 | Initiated | H.C. Wainwright | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | JMP Securities | Mkt Outperform |
| Dec-07-15 | Initiated | Jefferies | Buy |
| Dec-07-15 | Initiated | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Wave Life Sciences Ltd Stock (WVE) Latest News
Wave Life Sciences is a new Buy at Canaccord Genuity on near-term catalysts - MSN
Tan Aik Na sells Wave Life Sciences (WVE) shares for $194k - Investing.com Nigeria
Wave Life Sciences gains as JPMorgan suspends rating (update) - MSN
Applying big data sentiment scoring on Wave Life Sciences Ltd.Trade Risk Report & Community Consensus Stock Picks - Newser
Risk adjusted return profile for Wave Life Sciences Ltd. analyzedMarket Rally & Community Verified Watchlist Alerts - Newser
Wave Life Sciences gains as JPMorgan suspends rating (update) (WVE:NASDAQ) - Seeking Alpha
Wave Life Sciences Ltd. shares rise 2.69% intraday after Ocean Power Technologies, Inc. highlights marine energy innovations. - AInvest
Pattern Scan Adds Wave Life Sciences Ltd. to WatchlistTrade Ideas & Safe Entry Momentum Tips - newsimpact.co.kr
Wave Life Sciences Ltd. Recovery Linked to Earnings SurpriseJuly 2025 Highlights & High Accuracy Trade Signal Alerts - newsyoung.net
Wave Life Sciences director Henry sells $85k in shares By Investing.com - Investing.com Nigeria
Wave Life Sciences director Henry sells $85k in shares - Investing.com
Wave Life Sciences Shareholders Approve Key Proposals - MSN
Will Weaker Sales and Deeper Losses Shift Wave Life Sciences' (WVE) Investment Narrative? - simplywall.st
Is Wave Life Sciences Ltd. the Top Chart Pick This WeekAI Based High Gain Watchlist Scanner Shared - beatles.ru
Wave Life Sciences Director Sells 1,127 Shares for $8.75 Each. - AInvest
Oppenheimer Initiates Wave Life Sciences(WVE.US) With Buy Rating, Announces Target Price $24 - 富途牛牛
CCORF Initiates Wave Life Sciences(WVE.US) With Buy Rating, Announces Target Price $19 - 富途牛牛
Wave Life Sciences Highlights RNA Platform Advancements - TipRanks
A Quick Look at Today's Ratings for Wave Life Sciences(WVE.US), With a Forecast Between $18 to $24 - 富途牛牛
Wave Life Sciences stock a new Buy at Canaccord Genuity (WVE) - Seeking Alpha
Wave Life Sciences stock initiated with Buy rating by Canaccord - Investing.com Australia
This AeroVironment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Wave Life Sciences Ltd. shares rise 6.03% premarket after OraSure Technologies appoints new Chief Commercial Officer. - AInvest
Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Trimmed Their Revenue Forecasts By 13% - simplywall.st
Wave Life Sciences signals key Q3 and Q4 data catalysts as INHBE and AATD programs advance - MSN
When is Wave Life Sciences Ltd. stock expected to show significant growthSuperior stock growth - Jammu Links News
What analysts say about Wave Life Sciences Ltd. stockConsistent triple-digit returns - Jammu Links News
Earnings Update: Wave Life Sciences Ltd. (NASDAQ:WVE) Just Reported And Analysts Are Trimming Their Forecasts - 富途牛牛
How many analysts rate Wave Life Sciences Ltd. as a “Buy”Triple-digit wealth increases - Jammu Links News
What are analysts’ price targets for Wave Life Sciences Ltd. in the next 12 monthsUnlock powerful trading strategies for gains - Jammu Links News
What is Wave Life Sciences Ltd. company’s growth strategyDiscover undervalued stocks ready to soar - Jammu Links News
Is Wave Life Sciences Ltd. a growth stock or a value stockExceptional profit potential - Jammu Links News
What are the latest earnings results for Wave Life Sciences Ltd.Capitalize on emerging market sectors - Jammu Links News
How does Wave Life Sciences Ltd. compare to its industry peersBuild a portfolio that withstands market volatility - Jammu Links News
Insights Into WAVE Life Sciences's Upcoming Earnings - 富途牛牛
How strong is Wave Life Sciences Ltd. company’s balance sheetSmart Portfolio Outlook For Consistent Profits - Jammu Links News
Why is Wave Life Sciences Ltd. stock attracting strong analyst attentionPost Market Updates For Consistent Profits - Jammu Links News
Wave Life Sciences Ltd. shares rise 2.72% intraday after TELUS CORPORATION's ESG initiatives and new product focus. - AInvest
WAVE Life Sciences Reports Q2 2025 Earnings: RNA Editing Progress Amid Revenue Decline and Strong Cash Position - AInvest
Wave Life Sciences Second Quarter 2025 Earnings: Misses Expectations - simplywall.st
Wave Life Sciences Ltd. (NASDAQ:WVE) Q2 2025 Earnings Call Transcript - Insider Monkey
Need To Know: The Consensus Just Cut Its Wave Life Sciences Ltd. (NASDAQ:WVE) Estimates For 2025 - Yahoo Finance
Wave Life Sciences Earnings Call: Clinical Advances Amid Financial Challenges - TipRanks
Wave Life Sciences Ltd Stock (WVE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):